症状出现6小时后血管内取栓术的最佳患者选择评估:AURORA数据库汇总分析
本研究基于AURORA协作组汇总的随机临床试验患者水平数据,评估发病6至24小时内血管内取栓术(EVT)在三种基线影像特征亚组中的获益。结果显示,临床不匹配亚组和目标灌注不匹配亚组患者接受EVT均与90天残疾减少相关,而影像特征未定亚组未见显著获益。
要点
- 临床不匹配或目标灌注不匹配的患者在6-24小时行EVT可减少残疾。
- 影像特征未定患者未观察到显著治疗获益。
- 两个不匹配亚组与未定亚组之间的治疗效应存在显著交互作用。
核心结论
- 在6至24小时治疗时间窗内,临床不匹配亚组和目标灌注不匹配亚组患者接受EVT的获益相似。
- 这些发现支持EVT用于符合任一影像不匹配特征标准的6至24小时时间窗患者。
研究设计与样本
- AURORA协作组汇总了2010年1月1日至2021年3月1日发表的随机临床试验的患者水平数据。
- 纳入在最后已知良好时间后6至24小时内随机化的缺血性卒中患者,共505例。
- EVT组266例(平均年龄68.4岁,SD 13.8;女性146例,54.9%),对照组239例(平均年龄68.7岁,SD 13.7;男性126例,52.7%)。
- 采用混合效应模型进行分析,固定效应包括感兴趣的参数。
主要发现
- 临床不匹配亚组295例中,EVT与90天残疾减少相关(OR 3.57;95% CI 2.29-5.57;P < .001)。
- 目标灌注不匹配亚组359例中,EVT与90天残疾减少相关(OR 3.13;95% CI 2.10-4.66;P = .001)。
- 两个亚组在全部三个治疗时间三分位区间均观察到显著获益,第三分位(763-1440分钟)OR最高:临床不匹配亚组OR 4.95(95% CI 2.20-11.16;P < .001),目标灌注不匹配亚组OR 5.01(95% CI 2.37-10.60;P < .001)。
- 132例(26.1%)影像特征未定患者未见显著治疗获益(OR 1.59;95% CI 0.82-3.06;P = .17)。
- 临床与目标灌注不匹配亚组对比未定亚组的治疗效应交互作用显著(OR 2.28;95% CI 1.11-4.70;P = .03)。
关键数值与推荐
- 主要结局为90天改良Rankin量表评估的残疾减少。
- 治疗时间三分位区间:第一分位360-574分钟(6.0-9.5小时),第二分位575-762分钟(9.6-12.7小时),第三分位763-1440分钟(12.8-24.0小时)。
临床怎么用
- 对于发病6至24小时的缺血性卒中患者,若符合临床不匹配或目标灌注不匹配的影像特征,可考虑行EVT。
- 影像特征未定的患者行EVT的获益不显著,决策需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal imaging approach for identifying patients who may benefit from endovascular thrombectomy (EVT) beyond 6 hours after they were last known well is unclear. Six randomized clinical trials (RCTs) have evaluated the efficacy of EVT vs standard medical care among patients with ischemic stroke. OBJECTIVE: To assess the benefits of EVT among patients with 3 baseline imaging profiles using a pooled analysis of RCTs. DATA SOURCES: The AURORA (Analysis of Pooled Data from Randomized Studies of Thrombectomy More Than 6 Hours After Last Known Well) Collaboration pooled patient-level data from the included clinical trials. STUDY SELECTION: An online database search identified RCTs of endovascular stroke therapy published between January 1, 2010, and March 1, 2021, that recruited patients with ischemic stroke who were randomized between 6 and 24 hours after they were last known well. DATA EXTRACTION/SYNTHESIS: Data from the final locked database of each study were provided. Data were pooled, and analyses were performed using mixed-effects modeling with fixed effects for parameters of interest. MAIN OUTCOMES AND MEASURES: The primary outcome was reduction in disability measured by the modified Rankin Scale at 90 days. An evaluation was also performed to examine whether the therapeutic response differed based on imaging profile among patients who received treatment based on the time they were last known well. Treatment benefits were assessed among a clinical mismatch subgroup, a target perfusion mismatch subgroup, and an undetermined profile subgroup. The primary end point was assessed among these subgroups and during 3 treatment intervals (tercile 1, 360-574 minutes [6.0-9.5 hours]; tercile 2, 575-762 minutes [9.6-12.7 hours]; and tercile 3, 763-1440 minutes [12.8-24.0 hours]). RESULTS: Among 505 eligible patients, 266 (mean [SD] age, 68.4 [13.8] years; 146 women [54.9%]) were assigned to the EVT group and 239 (mean [SD] age, 68.7 [13.7] years; 126 men [52.7%]) were assigned to the control group. Among 295 patients in the clinical mismatch subgroup and 359 patients in the target perfusion mismatch subgroup, EVT was associated with reductions in disability at 90 days vs no EVT (clinical mismatch subgroup, odds ratio [OR], 3.57; 95% CI, 2.29-5.57; P < .001; target perfusion mismatch subgroup, OR, 3.13; 95% CI, 2.10-4.66; P = .001). Statistically significant benefits were observed in all 3 terciles for both subgroups, with the highest OR observed for tercile 3 (clinical mismatch subgroup, OR, 4.95; 95% CI, 2.20-11.16; P < .001; target perfusion mismatch subgroup, OR, 5.01; 95% CI, 2.37-10.60; P < .001). A total of 132 patients (26.1%) had an undetermined imaging profile and no significant treatment benefit (OR, 1.59; 95% CI, 0.82-3.06; P = .17). The interaction between treatment effects for the clinical and target perfusion mismatch subgroups vs the undetermined profile subgroup was significant (OR, 2.28; 95% CI, 1.11-4.70; P = .03). CONCLUSIONS AND RELEVANCE: In this study, EVT was associated with similar benefit among patients in the clinical mismatch and target perfusion mismatch subgroups during the 6- to 24-hour treatment interval. These findings support EVT as a treatment for patients meeting the criteria for either of the imaging mismatch profiles within the 6- to 24-hour interval.
引用
- Albers GW, Lansberg MG, Brown S, et al. Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset: A Pooled Analysis of the AURORA Database. JAMA Neurol. 2021. PMID: 34309619. doi:10.1001/jamaneurol.2021.2319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。